Phathom Pharmaceuticals Reaffirms Full-Year 2026 Guidance
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Intel Shares Fall as Profit Disappoints and PC Outlook Weakens
Intel shares fell as much as 20% in after-hours trading Thursday after the company reported disappointing third-quarter results and forecast a prolonged slowdown in PC sales.
H impact | EARNINGS | Oct 29, 2026, 09:30 PM UTC
Amazon CEO Expects Ad Sales Growth to Return to High Teens in Q4
M impact | EARNINGS | Oct 29, 2026, 09:23 PM UTC
Amazon reports disappointing results amid AI costs
A wire headline says AI costs weigh on Amazon’s results, which disappointed.
M impact | EARNINGS | Oct 29, 2026, 09:19 PM UTC
Amazon Third-Quarter Results Miss Views as AI Spending Drives Negative Cash Flow
Amazon's third-quarter results missed Wall Street views, while AI spending drove negative cash flow.
M impact | EARNINGS | Oct 29, 2026, 09:18 PM UTC
Jack Henry forecasts $30 million in fiscal 2027 deconversion revenue
M impact | EARNINGS | Oct 29, 2026, 09:16 PM UTC
Minerals Technologies Q3 Sales Slightly Beat Estimates
Minerals Technologies reported Q3 sales slightly above estimates, citing steel and foundry demand.
M impact | EARNINGS | Oct 29, 2026, 09:16 PM UTC